NCT04615325View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

January 4, 2023

Study Completion Date

January 4, 2023

Conditions

Geographic Atrophy

Interventions

DRUG

RO7303359

RO730359 will be administered as a single intravitreal injection.

Trial Locations (12)

28803

Western Carolina Retinal Associate PA, Asheville

32901

Florida Eye Associates, Melbourne

37203

Tennessee Retina PC., Nashville

48073

Associated Retinal Consultants PC, Royal Oak

60452

University Retina and Macula Associates, PC, Oak Forest

75231

Retina Foundation of the Southwest, Dallas

78750

Austin Clinical Research LLC, Austin

80230

Colorado Retina Associates, PC, Denver

89502

Sierra Eye Associates, Reno

93454

California Retina Consultants - Santa Maria, Santa Maria

94040

Northern California Retina Vitreous Associates, Mountain View

95825

Retinal Consultants Med Group, Sacramento

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT04615325 - A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter